Special Issue

Recent Advances in Improving or Preserving Therapeutic Potential of Extracellular Vesicles as Regenerative Medicines

Message from the Guest Editors

Extracellular vesicles (EVs) are intercellular communication tools that carry effector biomolecules inside to mediate normal physiological processes and disease pathogenesis. In particular, regenerative and immunomodulatory EVs have been highly regarded as innate bio-therapeutics to treat a variety of diseases during the past decade. Although stem cells are the main source of producing these EVs. related research has expanded to utilize immune cells and specific organ-originated cells. We are seeking recent efforts in the field of regenerative medicine for enhancing the therapeutic efficacy, efficiency, and stability of EVs to foster their clinical translation using three specific approaches: (1) preconditioning to improve EV bioactivity by applying chemical or physical stimuli, (2) surface modification for transporting EVs properly to the lesion by introduction of targeting components on them, and (3) development of formulations to preserve the structural integrity and therapeutic components of EVs.

Guest Editors

Prof. Dr. Jae Hyung Park

School of Chemical Engineering, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Suwon 16419, Republic of Korea

Dr. Seunglee Kwon

School of Chemical Engineering, Sungkyunkwan University, Suwon 16419. Korea

Deadline for manuscript submissions

closed (10 August 2022)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/98108

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

